Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Q: What equity awards did Vor Bio (VOR) grant as inducement to new employees?

Vor Bio granted stock options to purchase an aggregate of 83,600 shares of common stock and RSUs representing 17,900 shares to six newly hired employees as material inducements to employment under its 2023 Inducement Plan.

Q: What is the exercise price and term of the new Vor Bio (VOR) stock options?

The stock options have a term of ten years and an exercise price of $22.64 per share, which equals the closing price of Vor Bio’s common stock on the September 1, 2026 grant date.

Q: How do the Vor Bio (VOR) inducement stock options vest for new hires?

The stock options vest over four years: 25% of the shares vest after 12 months, and the remaining 75% vest in equal monthly installments over the following 36 months, subject to continued employment.

Q: What is the vesting schedule for the Vor Bio (VOR) inducement RSUs?

The RSUs vest over four years: 25% of the shares vest after 12 months, and the remaining 75% vest in equal quarterly installments over the following 36 months, contingent on the employees’ continued employment.

Q: Under which plan were Vor Bio’s (VOR) inducement grants made and what Nasdaq rule applies?

The stock options and RSUs were granted under the Vor Biopharma 2023 Inducement Plan and are described as material inducements to employment made in accordance with Nasdaq Listing Rule 5635(c)(4).

Vor Bio discloses time-based vesting stock option and RSU inducement grants for six new hires under its 2023 Inducement Plan.

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

Vor Bio (VOR) granted inducement equity awards to six newly hired employees on September 1, 2026 under its 2023 Inducement Plan and Nasdaq Listing Rule 5635(c)(4).

The awards consist of stock options to purchase an aggregate of 83,600 shares and RSUs covering 17,900 shares of common stock. The options have a ten-year term and an exercise price of $22.64, equal to the closing price on the grant date. Both options and RSUs vest over four years, with 25% vesting after 12 months and the remainder vesting over the following 36 months, subject to continued employment and the applicable award agreements.

Argus Sep 8 session

+0.20% close to close Open Argus

Details

News Market Reaction – VOR

On Sep 8, the first trading day after this news, VOR closed 0.20% above the previous close.

Data tracked by StockTitan Argus for the Sep 8 session.

Key Figures

Stock options: 83,600 shares Restricted stock units: 17,900 shares Recipients: 6 employees +4 more

Stock options: 83,600 shares; Granted to six newly hired employees
Restricted stock units: 17,900 shares; Granted to six newly hired employees
Recipients: 6 employees; Newly hired employees
Exercise price: $22.64 per share; Equal to the closing price on the grant date
Option term: 10 years; Stock options
Option vesting: 4 years; 25% after 12 months and remainder monthly over 36 months
RSU vesting: 4 years; 25% after 12 months and remainder quarterly over 36 months

Historical Context

5 past events · Latest: Sep 01

5 events

Sep 01
Conference participation

24h Move

+0.7%

Management announced participation in several September investor conferences.
Aug 11
Quarterly earnings

24h Move

+0.9%

Reported second-quarter results and continued Phase 3 development progress.
Aug 03
Inducement grant

24h Move

+3.9%

Granted options and RSUs to five newly hired employees.
Jul 07
Board appointment

24h Move

+1.0%

Appointed David Zaccardelli to the board of directors.
Jul 02
Inducement grant

24h Move

-2.4%

Granted inducement equity awards to seven newly hired employees.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

rsus, nasdaq listing rule 5635(c)(4), inducement plan, exercise price

4 terms

rsus financial

"restricted stock units (“RSUs”) representing the right to receive"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

inducement plan financial

"under the Vor Biopharma Inc. 2023 Inducement Plan"

An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.

exercise price financial

"an exercise price of $22.64 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

09/04/2026 - 04:05 PM EDT

BOSTON, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on September 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 83,600 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 17,900 shares of Vor Bio’s common stock to 6 newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).

The stock options have a ten-year term, and an exercise price of $22.64 per share, which is equal to the closing price of Vor Bio’s common stock on the grant date of the stock options. The options will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting monthly over the following 36 months, subject to the employees’ continued employment with Vor Bio on such vesting dates. The RSUs will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting quarterly over the following 36 months, subject to the employees’ continued employment with Vor Bio on such vesting dates. The options and RSUs are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an award agreement covering the grants.

About Vor Bio

Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com

Media & Investor Contacts:
Carl Mauch
cmauch@vorbio.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Vor Bio (VOR) grant as inducement to new employees?

Vor Bio granted stock options to purchase an aggregate of 83,600 shares of common stock and RSUs representing 17,900 shares to six newly hired employees as material inducements to employment under its 2023 Inducement Plan.

What is the exercise price and term of the new Vor Bio (VOR) stock options?

The stock options have a term of ten years and an exercise price of $22.64 per share, which equals the closing price of Vor Bio’s common stock on the September 1, 2026 grant date.

How do the Vor Bio (VOR) inducement stock options vest for new hires?

The stock options vest over four years: 25% of the shares vest after 12 months, and the remaining 75% vest in equal monthly installments over the following 36 months, subject to continued employment.

What is the vesting schedule for the Vor Bio (VOR) inducement RSUs?

The RSUs vest over four years: 25% of the shares vest after 12 months, and the remaining 75% vest in equal quarterly installments over the following 36 months, contingent on the employees’ continued employment.

Under which plan were Vor Bio’s (VOR) inducement grants made and what Nasdaq rule applies?

The stock options and RSUs were granted under the Vor Biopharma 2023 Inducement Plan and are described as material inducements to employment made in accordance with Nasdaq Listing Rule 5635(c)(4).

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)